AngioDynamics reported an EPS surprise of +33.33% and a revenue surprise of +1.35% for the quarter ended February 2026. The large EPS beat alongside only a slight revenue beat points to margin improvement or cost control driving results. Absent explicit forward guidance, the print supports near-term upside for the stock but the modest top-line beat tempers conviction on sustained revenue growth.
AngioDynamics reported an EPS surprise of +33.33% and a revenue surprise of +1.35% for the quarter ended February 2026. The large EPS beat alongside only a slight revenue beat points to margin improvement or cost control driving results. Absent explicit forward guidance, the print supports near-term upside for the stock but the modest top-line beat tempers conviction on sustained revenue growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
